# Metis Precision Medicine SB Srl

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/metis-precision-medicine-sb

- Industry: Pharmaceuticals
- Headquarters: Turin, Italy
- Website: www.metisprecisionmedicine.org
- Total disclosed funding: $0.9M
- Latest round: Seed (Dec 20, 2018)
- Investors on record: 2

## About

Metis Precision Medicine SB Srl is a healthcare company specializing in precision medicine, developing tailored therapeutic solutions and diagnostic tools to enhance patient care and outcomes across various medical conditions.Founded in 2017 in Turin, Italy, Metis Precision Medicine SB Srl focuses on precision medicine solutions. The company has raised capital through a SEED funding round led by Club Degli Investitori, which took place on December 20, 2018, securing EUR 0.80 mn. James Hughes, the founder, has a history of involvement in the healthcare sector, though specific details of previous ventures are not mentioned. Metis has participated in 2 deals to date, with the latest funding round comprising the total amount raised.Metis Precision Medicine specializes in developing advanced solutions in the field of precision medicine, focusing on tailored therapeutic approaches for various medical conditions. Their core products include proprietary diagnostic tools and treatment plans, designed to leverage genetic and molecular data to optimize patient care. These innovations aim to address specific health issues by providing precise, individualized treatment options, thereby enhancing patient outcomes. The company targets a diverse client base, which includes healthcare providers, hospitals, research institutions, and pharmaceutical companies, facilitating a wide array of end-users, including patients with chronic illnesses and genetic disorders. Metis's products are distributed in several global markets, including North America, Europe, and parts of Asia, ensuring a broad reach within the precision medicine sector.In 2023, Metis Precision Medicine reported a revenue amount of EUR 0.00 with an EBITDA of EUR -278,295.60. Revenue generation occurs primarily through structured partnerships and direct sales to healthcare providers and institutions, engaging in B2B transactions that typically involve long-term contracts with healthcare organizations.Future growth plans for Metis Precision Medicine include the development of new products aimed at enhancing their diagnostic and therapeutic offerings. While specific upcoming product launches have not been detailed, the company is exploring opportunities to expand into new geographic markets, particularly targeting regions in Europe and Asia by 2025. The EUR 0.80 mn raised during the SEED funding round will be utilized to support these expansion efforts and ongoing product development, enhancing the company’s capabilities and reach.

## Funding rounds

- Seed, Dec 20, 2018, $0.9M — Club Degli Investitori, Italian Angels for Biotech

## Investors

- Club Degli Investitori (https://capitalatlas.ai/funds/club-degli-investitori) — Seed
- Italian Angels for Biotech — Seed